DYSTANCE 51, a phase 2/3 clinical trial of investigational suvodirsen in Duchenne muscular dystrophy

Webinar Wave

Suvodirsen (formerly known as WVE-210201) is an investigational stereopure oligonucleotide being developed as a potential treatment for boys with Duchenne muscular dystrophy with mutations amenable to exon 51 skipping. Wave Life Sciences is a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating illnesses.

Wave has initiated DYSTANCE 51, a global phase 2/3 clinical trial evaluating the efficacy and safety of suvodirsen. This informational webinar will present an overview of the suvodirsen program, including the DYSTANCE 51 Phase 2/3 clinical trial.


  • Shariq Ali, Vice President, Medical Affairs, Wave Life Sciences
  • Jeffrey Smith, Director, Patient Advocacy, Wave Life Sciences

Related Posts

Share This Page

Make an Impact

You can advance the care, treatment and cure for Duchenne muscular dystrophy. Contributions in any amount can truly make a difference and can be credited to a fundraiser or event from the list below.